428 related items for PubMed ID: 17513327
1. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria.
Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, Kirschstein M, Linné T.
J Am Soc Nephrol; 2007 Jun; 18(6):1880-8. PubMed ID: 17513327
[Abstract] [Full Text] [Related]
2. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
Manno C, Torres DD, Rossini M, Pesce F, Schena FP.
Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
[Abstract] [Full Text] [Related]
3. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
Lv J, Zhang H, Chen Y, Li G, Jiang L, Singh AK, Wang H.
Am J Kidney Dis; 2009 Jan; 53(1):26-32. PubMed ID: 18930568
[Abstract] [Full Text] [Related]
4. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, Tang AW, Wong TY, Yung CY, Yung JC, Yu AW, Szeto CC, HKVIN Study Group.
Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
[Abstract] [Full Text] [Related]
5. Treatment of IgA nephropathy with angiotensin converting enzyme inhibitors: design of a prospective randomized multicenter trial.
Coppo R, Chiesa M, Peruzzi L, Amore A.
J Nephrol; 2001 May; 14(6):447-52. PubMed ID: 11783600
[Abstract] [Full Text] [Related]
6. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
Esnault VL, Brown EA, Apetrei E, Bagon J, Calvo C, DeChatel R, Holdaas H, Krcmery S, Kobalava Z, Amlodipine Versus Enalapril in Renal failure (AVER) Study Group.
Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
[Abstract] [Full Text] [Related]
7. Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy.
Bazzi C, Rizza V, Paparella M, Casellato D, Napodano P, Olivieri G, D'Amico G.
J Nephrol; 2009 Mar; 22(3):387-96. PubMed ID: 19557716
[Abstract] [Full Text] [Related]
8. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency.
Hou FF, Xie D, Zhang X, Chen PY, Zhang WR, Liang M, Guo ZJ, Jiang JP.
J Am Soc Nephrol; 2007 Jun; 18(6):1889-98. PubMed ID: 17494885
[Abstract] [Full Text] [Related]
9. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.
Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P.
N Engl J Med; 1996 Apr 11; 334(15):939-45. PubMed ID: 8596594
[Abstract] [Full Text] [Related]
10. Effects of co-administration of urokinase and benazepril on severe IgA nephropathy.
Chen X, Qiu Q, Tang L, Liu S, Cai G, Liu H, Xie Y.
Nephrol Dial Transplant; 2004 Apr 11; 19(4):852-7. PubMed ID: 15031340
[Abstract] [Full Text] [Related]
11. Prospective randomized controlled multicenter trial on steroids plus ramipril in proteinuric IgA nephropathy.
Manno C, Gesualdo L, D'Altri C, Rossini M, Grandaliano G, Schena FP.
J Nephrol; 2001 Apr 11; 14(4):248-52. PubMed ID: 11506246
[Abstract] [Full Text] [Related]
12. The effects of angiotensin-converting enzyme gene polymorphism on the progression of immunoglobulin A nephropathy in Malaysian patients.
Draman CR, Kong NC, Gafor AH, Rahman AF, Zainuddin S, Mustaffa WM, Radzi AM, Shamsul AS.
Singapore Med J; 2008 Nov 11; 49(11):924-9. PubMed ID: 19037561
[Abstract] [Full Text] [Related]
13. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study.
Maschio G, Cagnoli L, Claroni F, Fusaroli M, Rugiu C, Sanna G, Sasdelli M, Zuccalà A, Zucchelli P.
Nephrol Dial Transplant; 1994 Nov 11; 9(3):265-9. PubMed ID: 8052432
[Abstract] [Full Text] [Related]
14. Angiotensin-converting enzyme genotype and outcome in pediatric IgA nephropathy.
Santos NM, Ault BH, Gharavi AG, Kritchevsky SB, Quasney MW, Jackson EC, Fisher KA, Woodford SY, Mitchell BL, Gaber LW, Arheart KL, Wyatt RJ.
Pediatr Nephrol; 2002 Jul 11; 17(7):496-502. PubMed ID: 12172761
[Abstract] [Full Text] [Related]
15. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group.
Hogg RJ, Lee J, Nardelli N, Julian BA, Cattran D, Waldo B, Wyatt R, Jennette JC, Sibley R, Hyland K, Fitzgibbons L, Hirschman G, Donadio JV, Holub BJ, Southwest Pediatric Nephrology Study Group.
Clin J Am Soc Nephrol; 2006 May 11; 1(3):467-74. PubMed ID: 17699247
[Abstract] [Full Text] [Related]
16. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
[Abstract] [Full Text] [Related]
17. Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.
Locatelli F, Carbarns IR, Maschio G, Mann JF, Ponticelli C, Ritz E, Alberti D, Motolese M, Janin G, Zucchelli P.
Kidney Int Suppl; 1997 Dec 20; 63():S63-6. PubMed ID: 9407424
[Abstract] [Full Text] [Related]
18. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
Trimarchi H, Muryan A, Young P, Forrester M, Iotti A, Pereyra H, Lombi F, Seminario O, Alonso M, Iotti R.
Medicina (B Aires); 2007 Dec 20; 67(5):445-50. PubMed ID: 18051227
[Abstract] [Full Text] [Related]
19. Effects of angiotensin converting enzyme inhibitor on renal function in patients of membranoproliferative glomerulonephritis with mild to moderate renal insufficiency.
Giri S, Mahajan SK, Sen R, Sharma A.
J Assoc Physicians India; 2002 Oct 20; 50():1245-9. PubMed ID: 12568207
[Abstract] [Full Text] [Related]
20. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C, Conte G.
Am J Kidney Dis; 2008 Sep 20; 52(3):475-85. PubMed ID: 18468748
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
